NIH, Sponsors, Non-Profits Form Accelerating Medicines Partnership

February 6, 2014

Applied Clinical Trials

The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership

The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership (AMP) in the hopes of accelerating biomarker identification and drug targets in four diseases—Alzheimer's, Type II diabetes, rheumatoid arthritis and lupus—through data sharing. At the foundation of the partnership is the agreement that the data and analyses generated will be made publicly available to the broad biomedical community.

The AMP partners, along with the NIH include FDA, as well as biopharma sponsors AbbVie, Biogen, BMS, GSK, J&J, Lilly, Merck, Pfizer, Sanofi and Takeda. Major disease associations include the Alzheimer’s Association, USAgainstAlzheimer’s, American Diabetes Association, Lupus Foundation of America, and the Rheumatology Research Foundation. All partners have developed research plans and are sharing costs, expertise, and resources in an integrated governance structure. The three- to five-year, milestone-driven pilot projects in these disease areas could set the stage for broadening AMP to other diseases and conditions.

Read the full release here.